24 related articles for article (PubMed ID: 9459044)
1. Effect of Omeprazole Administration on the Pharmacokinetics of Oral Extended-Release Nifedipine in Healthy Subjects.
Zhao L; Sun D; Tan ML; Xu M; Kinjo M; Feng K; Wang H; Lionberger R
Clin Pharmacol Ther; 2023 Nov; 114(5):1134-1141. PubMed ID: 37669218
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
Kukulka M; Nudurupati S; Perez MC
Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
[TBL] [Abstract][Full Text] [Related]
3. Evidence of Reliable Gastro-Resistance of Novel Enteric Ready-to-Fill Capsules Simplifying Pharmaceutical Manufacturing.
Afonso Urich JA; Fedorko A; Hölzer B; Khinast J
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004571
[TBL] [Abstract][Full Text] [Related]
4. Formulation and evaluation of omeprazole tablets for duodenal ulcer.
Choudhury A; Das S; Bahadur S; Saha S; Roy A
Indian J Pharm Sci; 2010 Jul; 72(4):491-4. PubMed ID: 21218061
[TBL] [Abstract][Full Text] [Related]
5. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.
Thomson AB; Sinclair P; Matisko A; Rosen E; Andersson T; Olofsson B
Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045
[TBL] [Abstract][Full Text] [Related]
6. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole--a new formulation.
Armstrong D
Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
[No Abstract] [Full Text] [Related]
8. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
12. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Dent J
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
